Northern Trust’s PDS Biotechnology PDSB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $65.9K | Sell |
108,893
-34,980
| -24% | -$26.3K | ﹤0.01% | 4199 |
|
|
2025
Q4 | $111K | Buy |
143,873
+30,401
| +27% | +$27.4K | ﹤0.01% | 4120 |
|
|
2025
Q3 | $115K | Sell |
113,472
-8,743
| -7% | -$10.3K | ﹤0.01% | 4103 |
|
|
2025
Q2 | $163K | Buy |
122,215
+39,683
| +48% | +$53.9K | ﹤0.01% | 3999 |
|
|
2025
Q1 | $98.2K | Hold |
82,532
| – | – | ﹤0.01% | 4119 |
|
|
2024
Q4 | $135K | Sell |
82,532
-10,261
| -11% | -$27.2K | ﹤0.01% | 4097 |
|
|
2024
Q3 | $354K | Sell |
92,793
-147,331
| -61% | -$492K | ﹤0.01% | 3684 |
|
|
2024
Q2 | $704K | Sell |
240,124
-1,107
| -0.5% | -$3.54K | ﹤0.01% | 3377 |
|
|
2024
Q1 | $955K | Sell |
241,231
-8,459
| -3% | -$43.6K | ﹤0.01% | 3325 |
|
|
2023
Q4 | $1.24M | Buy |
249,690
+3,311
| +1% | +$16.5K | ﹤0.01% | 3236 |
|
|
2023
Q3 | $1.24M | Buy |
246,379
+8,230
| +3% | +$45.1K | ﹤0.01% | 3199 |
|
|
2023
Q2 | $1.2M | Buy |
238,149
+187,586
| +371% | +$1.23M | ﹤0.01% | 3288 |
|
|
2023
Q1 | $311K | Buy |
50,563
+1,232
| +2% | +$10.1K | ﹤0.01% | 3654 |
|
|
2022
Q4 | $651K | Buy |
49,331
+3,577
| +8% | +$25.2K | ﹤0.01% | 3413 |
|
|
2022
Q3 | $136K | Buy |
45,754
+5,240
| +13% | +$22.2K | ﹤0.01% | 4018 |
|
|
2022
Q2 | $148K | Sell |
40,514
-1,306
| -3% | -$6.21K | ﹤0.01% | 4035 |
|
|
2022
Q1 | $259K | Hold |
41,820
| – | – | ﹤0.01% | 4020 |
|
|
2021
Q4 | $339K | Buy |
41,820
+2,466
| +6% | +$26.5K | ﹤0.01% | 3961 |
|
|
2021
Q3 | $586K | Buy |
39,354
+3,061
| +8% | +$38.2K | ﹤0.01% | 3711 |
|
|
2021
Q2 | $455K | Hold |
36,293
| – | – | ﹤0.01% | 3751 |
|
|
2021
Q1 | $165K | Sell |
36,293
-12,124
| -25% | -$48.8K | ﹤0.01% | 4164 |
|
|
2020
Q4 | $103K | Buy |
48,417
+35,554
| +276% | +$77.9K | ﹤0.01% | 4107 |
|
|
2020
Q3 | $30K | Sell |
12,863
-49
| -0.4% | -$137 | ﹤0.01% | 4162 |
|
|
2020
Q2 | $26K | Buy |
12,912
+1,449
| +13% | +$1.61K | ﹤0.01% | 4132 |
|
|
2020
Q1 | $8K | Buy |
+11,463
| New | +$19.9K | ﹤0.01% | 4165 |
|
|
2019
Q1 | – | Sell |
-2,242
| Closed | -$14K | – | 4255 |
|
|
2018
Q4 | $14K | Hold |
2,242
| – | – | ﹤0.01% | 4179 |
|
|
2018
Q3 | $37K | Hold |
2,242
| – | – | ﹤0.01% | 4168 |
|
|
2018
Q2 | $46K | Sell |
2,242
-8,581
| -79% | -$179K | ﹤0.01% | 4130 |
|
|
2018
Q1 | $255K | Sell |
10,823
-578
| -5% | -$155K | ﹤0.01% | 3760 |
|
|
2017
Q4 | $2.14M | Sell |
11,401
-151
| -1% | -$30.4K | ﹤0.01% | 3106 |
|
|
2017
Q3 | $2.48M | Buy |
11,552
+5,567
| +93% | +$1.15M | ﹤0.01% | 3047 |
|
|
2017
Q2 | $1.23M | Sell |
5,985
-2,887
| -33% | -$569K | ﹤0.01% | 3388 |
|
|
2017
Q1 | $1.62M | Buy |
8,872
+679
| +8% | +$134K | ﹤0.01% | 3181 |
|
|
2016
Q4 | $2.05M | Buy |
8,193
+435
| +6% | +$98.8K | ﹤0.01% | 3076 |
|
|
2016
Q3 | $1.61M | Buy |
7,758
+316
| +4% | +$62.6K | ﹤0.01% | 3156 |
|
|
2016
Q2 | $1.5M | Buy |
7,442
+3,372
| +83% | +$596K | ﹤0.01% | 3181 |
|
|
2016
Q1 | $745K | Hold |
4,070
| – | – | ﹤0.01% | 3345 |
|
|
2015
Q4 | $1.02M | Buy |
+4,070
| New | +$1.31M | ﹤0.01% | 3319 |
|
Other funds holding PDSB
VCM
VFT
IWA
AC
Northern Trust's PDSB Position: Q1 2026 in Review
Northern Trust reduced its PDS Biotechnology (PDSB) stake by 24% in Q1 2026, selling an estimated $26.3K and leaving 108,893 shares worth $65.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4199.
Northern Trust first reported a position in PDSB in Q4 2015 and has held it in 38 quarters since. The position peaked at $2.48M in Q3 2017. 41 funds tracked by Wall St. Rank hold PDSB as of Q1 2026.
- Northern Trust held 108,893 shares of PDS Biotechnology worth $65.9K as of Q1 2026.
- Northern Trust sold 34,980 PDS Biotechnology shares in Q1 2026, an estimated $26.3K.
- PDS Biotechnology made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #4199 holding.
- Northern Trust first reported a position in PDS Biotechnology in Q4 2015 and has held it in 38 quarters since.
- Northern Trust's PDS Biotechnology position peaked at $2.48M in Q3 2017.
- 41 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2026.
Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.